FDA Responses to Criticism Over Antidepressants in Pregnancy
The U.S. Food and Drug Administration has pushed back against healthcare providers’ concerns regarding its approach to investigating the health risks associated with antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), during pregnancy.
Several health organizations, including the American College of Obstetricians and Gynecologists, have taken issue with FDA Commissioner Dr. Marty Makary, his agency, and participants of a panel discussion he led last month, alleging that they propagated “inaccurate” information and made “quirky” claims.
A notable claim from a panelist was that, “Adolescents exposed to SSRIs in the uterus displayed higher anxiety and depression symptoms compared to those who were not exposed.”
An FDA spokesperson defended the agency, asserting that criticism of the institution’s expert advisory process stems from political motivations.
Dr. Jay Ginrich, a developmental psychology professor at Columbia University Medical Center, mentioned during a panel discussion on July 21 that while SSRIs have long been prescribed to mothers suffering from depression, significant research only began recently to assess whether these medications impact the health of their children.
According to JAMA Medical News, no randomized clinical trials have been conducted, mostly due to ethical considerations. Yet, it’s estimated that 6% to 8% of pregnant women in the U.S. are prescribed SSRIs.
Ginrich, alongside Finnish researchers, explored the implications of in-utero SSRI exposure for human children after observing adverse behavioral and brain changes in rodent studies.
Research co-authored by Ginrich revealed through the journal Nature Communications that “adolescents exposed to SSRIs in the uterus exhibit higher anxiety and depressive symptoms than those who were not exposed, and greater activation of the amygdala when processing frightening stimuli.”
This study concluded that while SSRIs are a common treatment for perinatal maternal affective disorders, there is a need for a deeper understanding of how these medications affect early brain development and contribute to maladaptive behaviors.
Dr. Adam Urato, the chief of maternal-fetal medicine at Metrowest Medical Center in Massachusetts, expressed concern that many women believe SSRIs do not negatively impact their babies. He noted, “These medications change moms’ brains. Why wouldn’t they affect the fetus?”
He also referenced ultrasound studies showing different fetal movement and behavioral patterns in those exposed to SSRIs, adding, “After birth, these newborns show higher rates of anxiety and have more frequent hospitalizations in neonatal intensive care units.”
Urato emphasized that “the public needs better information,” suggesting that the FDA should enhance its warnings about SSRIs, particularly regarding risks like preterm birth and postpartum bleeding. He also pointed out the lack of communication on how SSRIs may alter fetal brain development.
Amidst these discussions, some organizations defending the use of SSRIs during pregnancy expressed discontent. Stephen Fleischman, president of the American School of Obstetrics and Gynecology, criticized the panel for its lack of balance, arguing that it underplayed the risks associated with untreated perinatal mood disorders. He maintained that SSRIs are generally safe during pregnancy and don’t significantly increase the risk of birth defects.
The current guidelines from the American School of Obstetrics and Gynecology encourage SSRIs as a first-line treatment for mothers from conception through the first year of the child’s life.
Fleischman also noted that the panel’s assertions might lead to fears that could hinder patients from seeking necessary care.
Dr. Marita Wills, CEO of the American Psychiatry Association, echoed these sentiments, stating her concerns about potential misunderstandings stemming from the panel’s comments. In a letter to Makary, she argued that misinterpretations of studies could add stigma and deter pregnant women from accessing care, despite existing evidence showing SSRIs can be safely taken for treatment.
The Maternal and Fetal Medicine Association also expressed outrage over the claims made during the panel, labeling them “unproven and inaccurate.”
In response to the backlash, an FDA spokesperson clarified that the agency’s expert advisory process is comprised of independent scientists, clinicians, and researchers who evaluate the latest scientific evidence and potential health risks.
“Commissioner Makary is focused on ensuring public health policies align with contemporary scientific standards,” the spokesperson said, dismissing accusations of political influence.
In conclusion, as the dialogue around SSRIs during pregnancy continues, the issue seems to be enveloped in a complex web of scientific inquiry, ethical considerations, and healthcare practices that underscore the importance of informed decision-making for expectant mothers.
